Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2514578 | 0.86 | ADORA3 (0.44) | ADORA1RAB9ATP53NPC1ADORA2A | |
| SCHEMBL11354763 | 0.79 | ALDH1A1 (0.45) | RAB9ANPC1MAPTSMN1; SMN2GAA | |
| SCHEMBL27350875 | 0.74 | MAPK1 (0.55) | MAPTALDH1A1MAP3K5MAPK1L3MBTL1 | |
| SCHEMBL164471 | 0.74 | — | — | |
| SCHEMBL11348714 | 0.71 | CCNE1 (0.44) | ADORA1RAB9ATP53NPC1ADORA2A | |
| SCHEMBL21743426 | 0.71 | L3MBTL1 (0.44) | ADORA1RAB9ATP53NPC1CYP1A2 | |
| SCHEMBL11353492 | 0.71 | CYP1A2 (0.49) | ADORA1RAB9ATP53NPC1ADORA2A | |
| SCHEMBL13134173 | 0.70 | RXFP1 (0.38) | RAB9ANPC1MAPTGAAALDH1A1 | |
| SCHEMBL27494779 | 0.70 | GAA (0.57) | RAB9ATP53NPC1MAPTSMN1; SMN2 | |
| SCHEMBL821743 | 0.69 | SMN1; SMN2 (0.61) | ADORA1RAB9ATP53NPC1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| US-5449682-A | Angiotensin II antagonists incorporating a substituted benzyl element | MERCK & CO., INC. (US) | 1995-09-12 | — | — | US | disclosed |
| US-5389660-A | Hypotensive agents | MERCK & CO., INC. (US) | 1995-02-14 | — | — | US | disclosed |
| US-5240938-A | Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring | MERCK & CO., INC. (US) | 1993-08-31 | — | — | US | disclosed |
| US-5164407-A | Hypotensive agents | MERCK & CO., INC. (US) | 1992-11-17 | — | — | US | disclosed |
| US-4249012-A | ANTISECRETORY ANTIULCER AGENTS | JOHN WYETH & BROTHER LTD. (GB) | 1981-02-03 | — | — | US | disclosed |
| US-4134984-A | AMIDO-SUBSTITUTED, ANTISECRETORY, ANTIULCER | JOHN WYETH & BROTHER LIMITED (GB) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | ADORA1 213/4885RAB9A 997/4885TP53 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.